We set our sight on a simple, but powerful vision to advance life science services toward a healthier world.
The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA.
We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Learn more
2023 Speaker Faculty
Dr. Cho is a trained behavior scientist and clinical epidemiologist. Her primary research interests are the psycho-social problems caused by cancer and its treatment. Dr. Cho is leading several qualitative and quantitative observational studies and clinical trials to find out the needs of cancer patients and their families, as well as to develop and implement the education programs both in clinic and in communities. As part of her work, she has had to develop or validate a variety of patient-reported outcome (PRO) measures for survivorship and health-related quality of life for cancer survivors in Korea and other Asian countries. She is active member of PROMIS Health Organization and currently responsible for PROMIS National Center in Korea.
Dr. Cho is also expert in research methods for digital therapeutics and conducting studies with SaMD and medical devices as well. She is advisory member for Digital Technologies Advisory board at Korean FDA.
Dr. Cho is currently the Director of Cancer Education Division at the Samsung Comprehensive Cancer Center, Director of Center for Clinical Epidemiology at Samsung Medical Center, and the Chair of the Department of Clinical Research Design and Evaluation at SAIHST, Sungkyunkwan University, Seoul, Korea. She also adjunct professor at Johns Hopkins Bloomberg School of Public Health, Balitmore, MD, USA.
Manager at DG Daiwa Ventures, a global VC based in Tokyo, specializing in healthcare and climate tech investments. Previously worked at Sumitomo Corporation, actively involved in supporting investments into infrastructure projects for Asian and African governments. Transitioned to the London office, engaged in M&A and post-merger integration in automotive, chemical, and logistics sectors. Joined DG Daiwa Ventures in Oct 2021, focusing on healthcare after witnessing the medical collapse during the pandemic. Notable investments include Akili, Limbix, Intellect, Allara, WHILL, and Winterlight etc.
Venue & Accomodation
DTx Asia 2023 will be coming to the Fairmont Singapore!
Centrally located in the heart of Singapore’s business, historical, cultural and shopping districts, just 20 minutes away from Singapore Changi International Airport (SIN).
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.
DTx Asia 2023 will be the 19th summit in the DTx series. We believe that getting the right mix of partners is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world-class audience.
You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.
Spaces are limited this year, please contact firstname.lastname@example.org to discuss opportunities for involvement.
Register for the Event
For pricing and booking options please click the button to go to the registration page.